MedTrace Logo

Dose-finding, Safety, Efficacy Trial of Topical Resiquimod in Patients With Multiple Actinic Keratosis Lesions

NCT01583816 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 218

Last updated 2015-12-15

No results posted yet for this study

Summary

A Dose-Finding Study of Resiquimod Evaluating Safety and Efficacy in Patients with Multiple Actinic Keratosis Lesions

Conditions

  • Actinic Keratosis

Interventions

DRUG

Resiquimod 0.03%

topical application

DRUG

Resiquimod 0.01%

topical application

DRUG

placebo

topical application

Sponsors & Collaborators

  • Spirig Pharma Ltd.

    lead INDUSTRY

Principal Investigators

  • Lars E French, MD · University Clinic of Dermatology, Zurich

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-05-31
Primary Completion
2013-11-30
Completion
2014-06-30

Countries

  • Germany
  • Switzerland

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01583816 on ClinicalTrials.gov